Zanubrutinib May Have PFS Edge Over Combo Therapy in CLL
Zanubrutinib monotherapy shows improved progression-free survival (PFS) compared to acalabrutinib-venetoclax in treatment-naive patients with chronic lymphocytic leukemia (CLL). The study indicates that while overall adverse event rates were similar, zanubrutinib was linked to higher rates of serious adverse events. These findings suggest zanubrutinib as a viable treatment option for CLL patients who might otherwise require more intensive combination therapies.
- ▪Zanubrutinib was associated with improved PFS compared to acalabrutinib-venetoclax in a fit subgroup of treatment-naive CLL patients.
- ▪In the unadjusted comparison, the 3-year PFS rates were 89.2% for zanubrutinib and 78.9% for acalabrutinib-venetoclax.
- ▪Zanubrutinib had higher rates of serious adverse events (47.5% vs 24.7%) compared to acalabrutinib-venetoclax.
Medscape files mainly under health. We currently carry 225 of its stories.
Opening excerpt (first ~120 words) tap to expand
TOPLINE: In indirect post hoc comparisons of data from two phase 3 trials, zanubrutinib monotherapy was associated with improved progression-free survival (PFS) over fixed‑duration acalabrutinib-venetoclax in a fit subgroup, treatment‑naive patients with chronic lymphocytic leukemia (CLL) after adjusting for baseline differences. Overall rates of adverse events were similar between the two treatment groups, but zanubrutinib was associated with higher rates of serious adverse events.METHODOLOGY: In the phase 3 SEQUOIA trial, zanubrutinib was associated with improved PFS compared with bendamustine-rituximab in treatment‑naive patients with CLL.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
